IRADIMED CORP (IRMD)
US46266A1097 - Common Stock
Overall IRMD gets a fundamental rating of 8 out of 10. We evaluated IRMD against 188 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, IRMD could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
IRMD had a positive operating cash flow in the past year.
In the past 5 years IRMD has always been profitable.
IRMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.76%, IRMD belongs to the top of the industry, outperforming 97.86% of the companies in the same industry.
Looking at the Return On Equity, with a value of 22.33%, IRMD belongs to the top of the industry, outperforming 96.26% of the companies in the same industry.
IRMD has a better Return On Invested Capital (19.59%) than 98.93% of its industry peers.
IRMD had an Average Return On Invested Capital over the past 3 years of 15.74%. This is significantly above the industry average of 8.23%.
The 3 year average ROIC (15.74%) for IRMD is below the current ROIC(19.59%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.76% | ||
| ROE | 22.33% | ||
| ROIC | 19.59% |
ROA(3y)14.97%
ROA(5y)12.26%
ROE(3y)18.14%
ROE(5y)14.8%
ROIC(3y)15.74%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.12%, IRMD belongs to the top of the industry, outperforming 95.72% of the companies in the same industry.
IRMD's Profit Margin has improved in the last couple of years.
IRMD has a Operating Margin of 29.91%. This is amongst the best in the industry. IRMD outperforms 97.33% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
IRMD has a Gross Margin of 77.14%. This is amongst the best in the industry. IRMD outperforms 90.37% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.91% | ||
| PM (TTM) | 26.12% | ||
| GM | 77.14% |
OM growth 3YN/A
OM growth 5Y9.17%
PM growth 3Y82.43%
PM growth 5Y4.85%
GM growth 3Y0.98%
GM growth 5Y0.05%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
Compared to 5 years ago, IRMD has more shares outstanding
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IRMD has an Altman-Z score of 40.56. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 40.56, IRMD belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 40.56 |
ROIC/WACC2.17
WACC9.05%
2.3 Liquidity
A Current Ratio of 9.21 indicates that IRMD has no problem at all paying its short term obligations.
IRMD's Current ratio of 9.21 is amongst the best of the industry. IRMD outperforms 90.37% of its industry peers.
IRMD has a Quick Ratio of 7.82. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD has a better Quick ratio (7.82) than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.21 | ||
| Quick Ratio | 7.82 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.48%, which is quite good.
The Earnings Per Share has been growing by 22.34% on average over the past years. This is a very strong growth
The Revenue has grown by 13.24% in the past year. This is quite good.
The Revenue has been growing by 16.58% on average over the past years. This is quite good.
EPS 1Y (TTM)13.48%
EPS 3Y53.4%
EPS 5Y22.34%
EPS Q2Q%0%
Revenue 1Y (TTM)13.24%
Revenue growth 3Y27.38%
Revenue growth 5Y16.58%
Sales Q2Q%11.03%
3.2 Future
IRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.01% yearly.
The Revenue is expected to grow by 14.79% on average over the next years. This is quite good.
EPS Next Y14.06%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
EPS Next 5YN/A
Revenue Next Year11.28%
Revenue Next 2Y11.02%
Revenue Next 3Y14.79%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 33.05 indicates a quite expensive valuation of IRMD.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than 73.26% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.96, IRMD is valued at the same level.
With a Price/Forward Earnings ratio of 29.62, IRMD can be considered very expensive at the moment.
75.40% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
IRMD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.05 | ||
| Fwd PE | 29.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 74.33% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRMD indicates a rather cheap valuation: IRMD is cheaper than 80.75% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.05 | ||
| EV/EBITDA | 28.11 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IRMD may justify a higher PE ratio.
A more expensive valuation may be justified as IRMD's earnings are expected to grow with 14.01% in the coming years.
PEG (NY)2.35
PEG (5Y)1.48
EPS Next 2Y9.82%
EPS Next 3Y14.01%
5. Dividend
5.1 Amount
IRMD has a Yearly Dividend Yield of 1.11%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 1.68, IRMD pays a better dividend. On top of this IRMD pays more dividend than 94.65% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.23, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.11% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
63.24% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP63.24%
EPS Next 2Y9.82%
EPS Next 3Y14.01%
IRADIMED CORP
NASDAQ:IRMD (11/22/2024, 3:07:47 PM)
52.88
-0.35 (-0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap669.99M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.11% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.05 | ||
| Fwd PE | 29.62 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.35
PEG (5Y)1.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.76% | ||
| ROE | 22.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 29.91% | ||
| PM (TTM) | 26.12% | ||
| GM | 77.14% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.21 | ||
| Quick Ratio | 7.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)13.48%
EPS 3Y53.4%
EPS 5Y
EPS Q2Q%
EPS Next Y14.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)13.24%
Revenue growth 3Y27.38%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y